These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17010604)

  • 41. Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
    Lu Y; Guo Z; Guo Y; Feng J; Chu F
    Bioorg Med Chem Lett; 2006 Feb; 16(4):915-9. PubMed ID: 16300944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent advances in de novo design strategy for practical lead identification.
    Honma T
    Med Res Rev; 2003 Sep; 23(5):606-32. PubMed ID: 12789688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.
    Khanna S; Sobhia ME; Bharatam PV
    J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
    Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
    ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand.
    Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3249-54. PubMed ID: 16621530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent developments in de novo design and scaffold hopping.
    Mauser H; Guba W
    Curr Opin Drug Discov Devel; 2008 May; 11(3):365-74. PubMed ID: 18428090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
    Ohashi M; Oyama T; Miyachi H
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design, synthesis, and structure-activity relationship of new isobenzofuranone ligands of protein kinase C.
    Baba Y; Ogoshi Y; Hirai G; Yanagisawa T; Nagamatsu K; Mayumi S; Hashimoto Y; Sodeoka M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2963-7. PubMed ID: 15125969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
    Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
    Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA; Sylte I
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2,4-diones as PPARgamma ligands.
    Barros CD; Amato AA; de Oliveira TB; Iannini KB; Silva AL; Silva TG; Leite ES; Hernandes MZ; Alves de Lima Mdo C; Galdino SL; Neves Fde A; Pitta Ida R
    Bioorg Med Chem; 2010 Jun; 18(11):3805-11. PubMed ID: 20471839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of a novel class of dual PPARgamma/delta agonists.
    Gonzalez IC; Lamar J; Iradier F; Xu Y; Winneroski LL; York J; Yumibe N; Zink R; Montrose-Rafizadeh C; Etgen GJ; Broderick CL; Oldham BA; Mantlo N
    Bioorg Med Chem Lett; 2007 Feb; 17(4):1052-5. PubMed ID: 17129725
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.
    Eeda V; Wu D; Lim HY; Wang W
    Bioorg Med Chem Lett; 2019 Nov; 29(22):126664. PubMed ID: 31591015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and SAR studies of indole-based MK2 inhibitors.
    Xiong Z; Gao DA; Cogan DA; Goldberg DR; Hao MH; Moss N; Pack E; Pargellis C; Skow D; Trieselmann T; Werneburg B; White A
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1994-9. PubMed ID: 18291646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.
    Choi J; Park Y; Lee HS; Yang Y; Yoon S
    Bioorg Med Chem; 2010 Dec; 18(23):8315-23. PubMed ID: 21030263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of potent N1-substituted indole melatonin receptor agonists.
    Tsotinis A; Eleutheriades A; Hough K; Sugden D
    Chem Commun (Camb); 2003 Feb; (3):382-3. PubMed ID: 12613623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.